<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139542">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01887782</url>
  </required_header>
  <id_info>
    <org_study_id>179/2012</org_study_id>
    <nct_id>NCT01887782</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Conventional vs Theta Burst rTMS</brief_title>
  <acronym>HFL vs TBS</acronym>
  <official_title>A Randomized Controlled Study of Conventional Versus Theta Burst Repetitive Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will compare a novel form of rTMS, intermittent Theta Burst Stimulation to the
      standard conventional high frequency left sided stimulation protocol.  The Left dorsolateral
      prefrontal cortex will be the site of stimulation in both treatment conditions.  The site of
      stimulation will be targeted using MRI co-registration. The study seeks to determine if the
      two treatment protocols have similar effectiveness in treating major depression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HAM-D17 score</measure>
    <time_frame>baseline, after each 5 treatment sessions, and 1, 4, and 12 weeks post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome measure is measured by a change in the HAM-D17 score from baseline to week 4. A 50% improvement in the score is considered response to rTMS. A final score of &lt;8 is categorized as remission.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>HFL rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iTBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HFL rTMS</intervention_name>
    <description>Magventure Cool B70 Coil with either RX100 or RX30 Stimulator</description>
    <arm_group_label>HFL rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iTBS</intervention_name>
    <description>Magventure Cool B70 Coil with either RX100 or RX30 Stimulator</description>
    <arm_group_label>iTBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  outpatients

          -  voluntary and competent to consent

          -  Mini-International Neuropsychiatric Interview (MINI) confirmed diagnosis of MDD,
             single, recurrent

          -  between ages 18-59

          -  failed to achieve a clinical response to an adequate dose of an antidepressant based
             on an Antidepressant Treatment History Form (ATHF) score of ≥ 3 in the current
             episode or have been unable to tolerate at least 2 separate trials of antidepressants
             of inadequate dose and duration (ATHF 1 or 2)

          -  have a score of ≥ 18 on the HAMD-17 item

          -  have had no increase or initiation of any psychotropic medication in the 4 weeks
             prior to screening

          -  able to adhere to the treatment schedule

          -  Pass the TMS adult safety screening (TASS) questionnaire

          -  have normal thyroid functioning based on pre-study blood work

        Exclusion Criteria:

          -  have a history of substance dependence or abuse within the last 3 months

          -  have a concomitant major unstable medical illness, cardiac pacemaker or implanted
             medication pump

          -  have active suicidal intent

          -  are pregnant

          -  have a lifetime MINI diagnosis of bipolar I or II disorder, schizophrenia,
             schizoaffective disorder, schizophreniform, delusional disorder, or current psychotic
             symptoms

          -  have a MINI diagnosis of obsessive-compulsive disorder, post-traumatic stress
             disorder (current or within the last year), anxiety disorder (generalized anxiety
             disorder, social anxiety disorder, panic disorder), or dysthymia assessed by a study
             investigator to be primary and causing greater impairment than MDD
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Blumberger, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Downar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto Western Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Missy Maher, BA</last_name>
    <phone>416-535-8501</phone>
    <phone_ext>36434</phone_ext>
    <email>missy.maher@camh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Terri Cairo</last_name>
    <phone>416-603-5667</phone>
    <email>Terri.Cairo@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J 1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Maher, BA</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>36434</phone_ext>
      <email>missy.maher@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Blumberger, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Cairo, BSc, CCRA</last_name>
      <phone>416 603 5667</phone>
      <email>terri.cairo@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Jonathan Downar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>June 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Daniel Blumberger</investigator_full_name>
    <investigator_title>Medical Head, Temerty Centre for Therapeutic Brain Intervention</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>magnetic</keyword>
  <keyword>brain stimulation</keyword>
  <keyword>treatment-resistant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
